ProPhase Labs, Inc. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
ProPhase Labs, Inc. (PRPH) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $42.00 thousand for the 12-month period ending 2010-12-31, per its 10-K filed 2013-03-28.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2013-03-28
- ProPhase Labs, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2010 was $42.00K, a 52.27% decline from fiscal 2009.
- ProPhase Labs, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2009 was $88.00K.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2010-12-31 | $42.00K 10-K · filed 2013-03-28 |
| 2009-12-31 | $88.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |